| Dr Kenneth Starr, MD | |
|
107 Nelson St, Arroyo Grande, CA 93420-3318 | |
| (805) 242-1360 | |
| Not Available |
| Full Name | Dr Kenneth Starr |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Addiction Medicine |
| Location | 107 Nelson St, Arroyo Grande, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861431595 | NPI | - | NPPES |
| H00866 | Other | CHAMPUS | |
| H00866 | Other | LIPA | |
| 8283574 | Medicaid | WA | |
| XPY196669 | Medicaid | CA | |
| H00866 | Other | GROUP HEALTH | |
| 057221014 | Other | BCBS | |
| 288397 | Medicaid | OR | |
| A032 | Other | CHAMPUS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD22323O (Oregon) | Secondary |
| 207RA0401X | Internal Medicine - Addiction Medicine | A105044 (California) | Primary |
| Entity Name | California Em-i Medical Services A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477502615 PECOS PAC ID: 3678487774 Enrollment ID: O20031113000451 |
News Archive
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).
› Verified 4 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).
› Verified 4 days ago
| Entity Name | Central Coast Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972535557 PECOS PAC ID: 9234114067 Enrollment ID: O20040623001681 |
News Archive
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).
› Verified 4 days ago
| Entity Name | Monterey Bay Observation Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205225505 PECOS PAC ID: 1052630514 Enrollment ID: O20150505002649 |
News Archive
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kenneth Starr, MD 105 S Main St, Templeton, CA 93465-9601 Ph: (805) 434-1869 | Dr Kenneth Starr, MD 107 Nelson St, Arroyo Grande, CA 93420-3318 Ph: (805) 242-1360 |
News Archive
A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.
A collaborative team of scientists, led by a group at The University of Texas Medical Branch at Galveston, have successfully protected nonhuman primates against one of the most deadly viruses in the world, Lassa fever, eight days after they became infected.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
Protein Discovery, Inc. and New Objective, Inc. today announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry ("top down" proteomics).
› Verified 4 days ago
Dr. Michael Zigelman, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 189 Vista Dr, Arroyo Grande, CA 93420 Phone: 805-489-9040 | |
Dr. Constantine Melitas, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Fair Oaks Ave Ste 220, Arroyo Grande, CA 93420 Phone: 805-434-5530 | |
Sharon Frances Billon, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 880 North Oak Park Blvd, Unit 103, Arroyo Grande, CA 93420 Phone: 805-474-9550 | |
Ena Sharma, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Fair Oaks Ave Ste 220, Arroyo Grande, CA 93420 Phone: 805-547-2224 Fax: 805-474-5276 | |
Erick W. Hjortsvang, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 584 Camino Mercado, Arroyo Grande, CA 93420 Phone: 805-474-9143 Fax: 805-474-9569 | |
Frank Eugene Scott Jr., D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 860 Oak Park Blvd, Suite 204, Arroyo Grande, CA 93420 Phone: 805-349-8903 Fax: 805-349-8938 | |
Nancy O'malley, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 260 Station Way, Arroyo Grande, CA 93420 Phone: 805-473-6201 |